What is the recommended tapering schedule for discontinuing Lexapro (escitalopram)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tapering Lexapro (Escitalopram): Recommended Protocol

Gradually reduce escitalopram over several weeks to months rather than stopping abruptly, as discontinuation symptoms are common and can be severe with SSRIs. 1, 2

FDA-Approved Guidance

The FDA label for escitalopram explicitly states: "A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate." 1

Recommended Tapering Schedule

Reduce the dose by 10-25% of the current dose (not the original dose) every 1-4 weeks, extending the taper over a minimum of several weeks to months. 3, 4

Specific Tapering Algorithm:

  • For patients on 10 mg daily: Reduce to 5 mg daily for 2-4 weeks, then consider further reduction to 2.5 mg daily for another 2-4 weeks before complete discontinuation 2, 5

  • For patients on 20 mg daily: Reduce to 15 mg for 2-4 weeks, then 10 mg for 2-4 weeks, then 5 mg for 2-4 weeks, then 2.5 mg for 2-4 weeks before stopping 3, 4

  • The taper rate must be determined by the patient's tolerance of withdrawal symptoms, not by a rigid schedule 6

  • Pauses in the taper are acceptable and often necessary when withdrawal symptoms emerge 6

Why Slow Tapering Matters

Escitalopram has a relatively short half-life compared to fluoxetine, making it more prone to withdrawal symptoms. 2, 5 Research demonstrates that tapers of 2-4 weeks (as traditionally recommended) show minimal benefit over abrupt discontinuation and are often not tolerated by patients. 4 Longer tapers over months, reaching doses much lower than minimum therapeutic doses, have shown greater success in reducing withdrawal symptoms. 4

The hyperbolic dose-reduction approach (reducing by percentage of current dose) is critical because SSRI receptor occupancy follows a hyperbolic curve—small dose reductions at lower doses produce proportionally larger changes in biological effect. 4

Monitoring for Withdrawal Symptoms

Monitor closely for discontinuation symptoms at each dose reduction before proceeding to the next step. 6, 3

Common withdrawal symptoms include:

  • Somatic symptoms: Dizziness, light-headedness, nausea, fatigue, myalgia, flu-like symptoms, sensory disturbances (electric shock sensations), sleep disturbances 2, 3

  • Psychological symptoms: Anxiety, agitation, crying spells, irritability, mood disturbances 2, 3

  • Symptoms typically emerge within days of dose reduction and can last days to months, with different symptoms having different durations 3

Managing Withdrawal Symptoms

If intolerable symptoms occur, return to the previous well-tolerated dose and slow the taper further. 1, 3

  • Mild symptoms can be managed with reassurance that they are usually transient 2

  • Severe symptoms require reinstating the previous dose and tapering more gradually (extending intervals between reductions to 4-6 weeks or longer) 2, 5, 3

  • Consider symptomatic management as needed (e.g., antiemetics for nausea, NSAIDs for myalgias) 6

Critical Pitfall to Avoid

Do not mistake withdrawal symptoms for relapse of depression. 2, 7 Withdrawal symptoms like low mood, anxiety, and irritability can mimic depression recurrence, potentially leading to unnecessary reinitiation of long-term antidepressant therapy. 7 The key distinction: withdrawal symptoms typically emerge within days of dose reduction and include prominent somatic features (dizziness, electric shock sensations, flu-like symptoms), whereas true relapse develops more gradually over weeks. 2, 3

Follow-Up Schedule

Follow up at least monthly during the taper, with more frequent contact (weekly or biweekly) during difficult phases or after each dose reduction. 6

Alternative Strategy: Switch to Fluoxetine

For patients experiencing severe withdrawal symptoms despite slow tapering, consider switching to fluoxetine before discontinuation. 5 Fluoxetine's exceptionally long half-life (4-6 days for the parent compound, 4-16 days for the active metabolite) provides a built-in buffer against withdrawal symptoms. 8, 5

  • Cross-taper by reducing escitalopram while starting fluoxetine 10 mg daily or every other morning 8
  • After 1-2 weeks on fluoxetine, discontinue escitalopram completely 5
  • Continue fluoxetine for 2-4 weeks, then discontinue without taper (fluoxetine's long half-life makes gradual taper unnecessary) 5

Patient Education

Educate patients before starting the taper that withdrawal symptoms are common, not dangerous, and do not indicate addiction. 2, 5 Reassurance throughout the discontinuation process is essential. 5 Some evidence suggests cognitive behavioral therapy may help ease distress during discontinuation, though this is based on limited data. 5

Realistic Timeline

The complete taper will likely require a minimum of 2-3 months, and possibly 4-6 months or longer for patients on higher doses or those with previous failed discontinuation attempts. 3, 4 The goal is durability of the taper, not speed. 6

References

Research

Clinical management of antidepressant discontinuation.

The Journal of clinical psychiatry, 1997

Research

Discontinuing antidepressants: Pearls and pitfalls.

Cleveland Clinic journal of medicine, 2022

Research

A review of the management of antidepressant discontinuation symptoms.

Therapeutic advances in psychopharmacology, 2015

Guideline

Benzodiazepine Discontinuation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Switching from Sertraline to Fluoxetine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.